108534-48-1

Upstream product

• 123-31-9 hydroquinone 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 391674-01-4 (4-benzyloxy-phenoxy)-tert-butyl-diphenyl-silane 
• 103-16-2 4-Benzyloxyphenol 
• 288-32-4 1H-imidazole 
• 1114567-55-3 1-(tert-butyldimethylsilyloxy)-4-(tert-butyldiphenylsilyloxy)benzene 

Downstream Products

• 391671-82-2 tert-Butyl-[4-((S)-1-oxiranylmethoxy)-phenoxy]-diphenyl-silane 
• 1312563-43-1 C₃₃H₄₃NO₄Si 
• 1312563-55-5 N-(3,4-dichlorophenyl)-4-((4-hydroxyphenoxy)methyl)-piperidine-1-carboxamide 
• 1312563-52-2 C₃₅H₃₈Cl₂N₂O₃Si 
• 1312563-38-4 N-(4-chlorophenyl)-4-((4-hydroxyphenoxy)methyl)-piperidine-1-carboxamide 
• 1312563-49-7 C₃₅H₃₉ClN₂O₃Si 
• 1312563-46-4 C₂₈H₃₅NO₂Si 
• 108534-52-7 4-(tert-Butyl-diphenyl-silanyloxy)-4-methoxy-cyclohexa-2,5-dienone 

Relevant academic research and scientific papers

Nickel Hydride Catalyzed Cleavage of Allyl Ethers Induced by Isomerization

This report discloses the deallylation of O - and N -allyl functional groups by using a combination of a Ni-H precatalyst and excess Bronsted acid. Key steps are the isomerization of the O - or N -allyl group through Ni-catalyzed double-bond migration followed by Bronsted acid induced O/N-C bond hydrolysis. A variety of functional groups are tolerated in this protocol, highlighting its synthetic value.

Phase-Transfer Catalyzed O-Silyl Ether Deprotection Mediated by a Cyclopropenium Cation

The use of a cyclopropenium cation as a phase-transfer catalyst for O-silyl ether deprotection is reported. Mechanistic insight into this deprotection methodology derived by linear free-energy relationships (LFER), quantum theory of atoms in molecules (QTAIM), and density functional theory (DFT) calculations are also provided.

HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS

This invention provides compounds of Formula I having the structure U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

4-Aminopiperidine ureas as potent selective agonists of the human β3-Adrenergic receptor

The preparation and structure-activity relationships (SARs) of potent agonists of the human β3-adrenergic receptor (AR) derived from a 4-aminopiperidine scaffold are described. Examples combine human β3-AR potency with selectivity over human β1-AR and/or human β2-AR agonism. Compound 29s was identified as a potent (EC50 = 1 nM) and selective (greater than 400-fold over β1- with no β2-AR agonism) full β3-AR agonist with in vivo activity in a transgenic mouse model of thermogenesis.